Enlivex ENLV 深 沪
已收盘 05-15 16:00:00 美东时间
0.7206
-0.012
-1.58%
华盛通- 最 高0.7399
- 今 开0.7135
- 成交量 22.49万股
- 最 低 0.7003
- 昨 收 0.7322
- 总市值 1.74亿
- 52周最高 2.10
- 市盈率 静 0.03
- 换手率 0.09%
- 52周最低 0.66
- 委 比 -66.67%
- 总股本 2.41亿
- 历史最高 44.90
- 量 比 0.89
- 振 幅 5.41%
- 历史最低 0.66
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enlivex receives Nasdaq non-compliance notice over sub-$1 share price
Enlivex(ENLV) was notified by Nasdaq that its share price stayed below the $1 minimum bid requirement for 30 consecutive business days. The company has until November 9, 2026, to regain compliance. I...
05-16 04:16
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex (NASDAQ:ENLV) with a Buy and raises the price target from $13 to $20.
04-07 19:17
Enlivex Therapeutics Q4 EPS $26.83 Beats $(0.13) Estimate
Enlivex Therapeutics (NASDAQ:ENLV) reported quarterly earnings of $26.83 per share which beat the analyst consensus estimate of $(0.13) by 20738.46 percent. This is a 12295.45 percent increase over losses of $(0.22) per
03-25 20:39
Enlivex Receives First FDA Approval For Phase2b Trial Of Allocetra For Age-Related Osteoarthritis
The U.S. Food and Drug Administration (FDA) has cleared Enlivex's Investigational New Drug (IND) application for Allocetra, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee
03-23 20:09
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex获得FDA批准启动针对中重度与年龄相关的膝关节骨关节炎患者的2b期全球多中心临床试验。该试验将评估其免疫疗法Allocetra™的疗效与安全性。此前，1/2a期临床试验已显示显著治疗效果。Enlivex采用双引擎价值创造模式，结合质量寿命项目与预测市场 treasury 策略推动发展。 Knee osteoarthritis影响数千万美国人，亟需新疗法。Trial将评估疼痛、功能及生活质量指标，以验证Allocetra™的潜力。
03-23 12:00
Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval
An announcement from Enlivex ( ($ENLV) ) is now available. On February 3, 2026,...
02-23 21:50
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Enlivex Therapeutics Ltd. announced the listing of its RAIN token on Kraken, the second-largest U.S.-based cryptocurrency exchange, on February 9, 2026. This listing aims to increase token access, enhance liquidity, and improve price discovery for RAIN. Kraken, with over 5.7 million users and $2 trillion in trading volume in 2025, is known for its security, regulatory compliance, and institutional-grade market participation. Rain serves as the go...
02-10 13:00
